Literature DB >> 15229305

Serum aldosterone and the incidence of hypertension in nonhypertensive persons.

Ramachandran S Vasan1, Jane C Evans, Martin G Larson, Peter W F Wilson, James B Meigs, Nader Rifai, Emelia J Benjamin, Daniel Levy.   

Abstract

BACKGROUND: Primary hyperaldosteronism is a well-recognized cause of secondary hypertension. It is unknown whether serum aldosterone levels within the physiologic range influence the risk of hypertension.
METHODS: We investigated the relation of baseline serum aldosterone levels to increases in blood pressure and the incidence of hypertension after four years in 1688 nonhypertensive participants in the Framingham Offspring Study (mean age, 55 years), 58 percent of whom were women. We defined an increase in blood pressure as an increment of at least one blood-pressure category (as defined by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) and defined hypertension as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or the use of antihypertensive medications.
RESULTS: At follow-up, the blood-pressure category had increased in 33.6 percent of the participants, and hypertension had developed in 14.8 percent. In multivariable models, a 16 percent increase in the risk of an elevation in blood pressure (P=0.002) and a 17 percent increase in the risk of hypertension (P=0.03) were observed per quartile increment in the serum aldosterone level. The highest serum aldosterone quartile, relative to the lowest, was associated with a 1.60-fold risk of an elevation in blood pressure (95 percent confidence interval, 1.19 to 2.14) and a 1.61-fold risk of hypertension (95 percent confidence interval, 1.05 to 2.46). The associations between the serum aldosterone level and blood-pressure outcomes were not significantly affected by adjustment for urinary sodium excretion or left ventricular thickness or internal dimensions.
CONCLUSIONS: In our community-based sample, increased aldosterone levels within the physiologic range predisposed persons to the development of hypertension. Copyright 2004 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229305     DOI: 10.1056/NEJMoa033263

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  143 in total

1.  Placental growth factor mediates aldosterone-dependent vascular injury in mice.

Authors:  Iris Z Jaffe; Brenna G Newfell; Mark Aronovitz; Najwa N Mohammad; Adam P McGraw; Roger E Perreault; Peter Carmeliet; Afshin Ehsan; Michael E Mendelsohn
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

2.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 3.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

4.  Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension.

Authors:  Philip A Kithas; Mark A Supiano
Journal:  J Am Geriatr Soc       Date:  2010-06-01       Impact factor: 5.562

Review 5.  The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes.

Authors:  Anand Vaidya; Jonathan S Williams
Journal:  Metabolism       Date:  2011-11-09       Impact factor: 8.694

6.  Does continuous positive airway pressure reduce aldosterone levels in patients with obstructive sleep apnea?

Authors:  Si-Jiu Yang; Xing-Tang Jiang; Xiao-Bin Zhang; Xiao-Wen Yin; Wei-Xian Deng
Journal:  Sleep Breath       Date:  2016-01-15       Impact factor: 2.816

7.  Aldosterone receptor antagonists: effective but often forgotten.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

Review 8.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 9.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

10.  Interindividual variation in serum sodium and longitudinal blood pressure tracking in the Framingham Heart Study.

Authors:  Rodrigo M Lago; Michael J Pencina; Thomas J Wang; Katherine J Lanier; Ralph B D'Agostino; William B Kannel; Ramachandran S Vasan
Journal:  J Hypertens       Date:  2008-11       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.